glimepiride/vildagliptin/metformin (G/V/M) / Laboratorios Silanes - LARVOL DELTA

Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure (clinicaltrials.gov) - P3 | N=162 | Completed | Sponsor: Laboratorios Silanes S.A. de C.V. | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Glycemic Improvement in Patients with Type 2 Diabetes under Treatment with a Fixed-Dose Combination Glimepiride/Vildagliptin/Metformin with Failure to Previous Dual Therapy (ADA 2024) - "Glimepiride/vildagliptin/metformin therapy improved glycemic control in patients with T2D and previous dual combination failure, this treatment was well tolerated with a low incidence of hypoglycemia."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure (clinicaltrials.gov) - P3 | N=172 | Recruiting | Sponsor: Laboratorios Silanes S.A. de C.V. | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2022 ➔ Apr 2024 | Trial primary completion date: Aug 2021 ➔ Mar 2024

Enrollment open • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus